文章基本信息

标题：How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK Therapy: A Case Report
本地全文：下载
作者：Antonello Sica ; Caterina Sagnelli ; Beniamino Casale 等
期刊名称：Healthcare
电子版ISSN：2227-9032
出版年度：2021
卷号：9
期号：2
页码：135
DOI：10.3390/healthcare9020135
出版社：MDPI Publishing
摘要：Background: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1–ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. These treatments are regarded as a bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT). Nowadays, transplant procedures and the monitoring of chemotherapy patients proceed very slowly because the SARS-CoV-2 pandemic has heavily clogged the hospitals in all countries. Results: A 40-year-old Caucasian woman was first seen at our clinical center in June 2020. She had ALCL ALK , a history of failure to two previous therapeutic lines and was in complete remission after 12 courses of brentuximab, still pending allo-SCT after two failed donor selections. Facing a new therapeutic failure, we requested and obtained authorization from the Italian drug regulatory agency to administer 250 mg of crizotinib twice a day, a drug incomprehensibly not registered for ALCL ALK . Conclusions: The response to crizotinib was optimal since no adverse event occurred, and CT-PET scans persisted negative; this drug has proved to be a valid bridge to allo-SCT.
关键词：crizotinib; anaplastic large cell lymphomas ALK ; bridge therapy in NHL ALK ; ALK patients; anticancer therapy crizotinib ; anaplastic large cell lymphomas ALK ; bridge therapy in NHL ALK ; ALK patients ; anticancer therapy